| Metals & Mining Industry | Materials Sector | Michael R. Cavanaugh CEO | OTC PINK Exchange | 56089M107 CUSIP |
| US Country | 18 Employees | - Last Dividend | 20 Jul 2016 Last Split | - IPO Date |
Range Impact, Inc., together with its subsidiaries, is a diversified company deeply embedded in the health and wellness sector in the United States. It distinguishes itself by operating across five key segments: Range Reclaim, Range Water, Range Security, Range Land, and Drug Development. Originally known as Malachite Innovations, Inc., the company underwent a rebranding to Range Impact, Inc. in December 2023, marking a significant milestone in its evolution. Since its inception in 2007, Range Impact has been headquartered in Cleveland, Ohio, and has expanded its services and products to cater to a wide array of needs from land reclamation to drug development, signifying a broad yet focused approach to environmental sustainability and healthcare.
Provides comprehensive land reclamation services targeted at both mining and non-mining companies across Appalachia. This involves the restoration of land that has been disturbed by mining activities, ensuring that it can be reused for other purposes or returned to its natural state.
Focuses on water restoration efforts, deploying advanced technologies and methodologies to clean and restore water resources that have been contaminated or negatively impacted by industrial activities.
Delivers environmental security services featuring technology-driven approaches. This segment caters to active and former mine sites, offering solutions that protect these areas from environmental and security threats.
Engages in incidental mining services, providing support and solutions to the mining industry. This involves a variety of services dedicated to enhancing the efficiency and environmental compliance of mining operations.
At the forefront of its commitment to health and wellness, Range Impact is developing VBX-100, a novel glycosylated tetrahydrocannabinol cannabinoid aimed at treating inflammatory conditions of the gastrointestinal tract. This development signifies the company's venture into biotechnology and its pursuit of innovative healthcare solutions.